Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease

ABSTRACT Metabolic dysfunction‐associated liver disease (MASLD) is a leading cause of liver disease in children. There is a paucity of data on potential biomarkers and therapeutic targets, especially in pediatric MASLD. We used mass spectrometry (MS)‐mediated proteomics followed by enzyme‐linked imm...

Full description

Saved in:
Bibliographic Details
Main Authors: Diego Paine‐Cabrera, Lisa K. Harvey, Michele T. Pritchard, John Thyfault, Antonio Artigues, Udayan Apte, Voytek Slowik
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Clinical and Translational Science
Subjects:
Online Access:https://doi.org/10.1111/cts.70271
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850163741136519168
author Diego Paine‐Cabrera
Lisa K. Harvey
Michele T. Pritchard
John Thyfault
Antonio Artigues
Udayan Apte
Voytek Slowik
author_facet Diego Paine‐Cabrera
Lisa K. Harvey
Michele T. Pritchard
John Thyfault
Antonio Artigues
Udayan Apte
Voytek Slowik
author_sort Diego Paine‐Cabrera
collection DOAJ
description ABSTRACT Metabolic dysfunction‐associated liver disease (MASLD) is a leading cause of liver disease in children. There is a paucity of data on potential biomarkers and therapeutic targets, especially in pediatric MASLD. We used mass spectrometry (MS)‐mediated proteomics followed by enzyme‐linked immunosorbent assay (ELISA) to identify potential biomarkers and therapeutic targets in pediatric MASLD. Serum samples were collected from pediatric subjects without (n = 56) and with MASLD (n = 72). Initial screen using MS‐based proteomics identified 6 upregulated (adenosine deaminase 2, sex hormone‐binding globulin (SHBG), inter‐alpha‐trypsin inhibitor heavy chain H1 (ITIH1), fructose‐bisphosphate aldolase A, type II cytoskeletal 2 epidermal keratine, N‐acetylmuramoyl‐L‐alanine amidase) and 3 downregulated (alcohol dehydrogenase 4 (ADH4), fructose‐bisphosphate aldolase B (ALDOB), serum albumin) proteins in the MASLD group. Confirmatory studies using ELISA were performed for the 2 strongest upregulated proteins (SHBG and ITIH1) and two top downregulated proteins (ADH4 and ALDOB). Correlation of ELISA results with clinical data revealed that SHBG had strong associations with BMI, ALT, and HgbA1c (p < 0.05). ADH4 had strong associations with BMI and HgbA1c (p < 0.05). ITIH1 and ALDOB had no strong correlations with common clinical parameters of MASLD. Area under ROC Curve revealed statistically significant ability of SHBG (494 nmol/L, sensitivity = 98%, specificity 80%) and ADH4 (2.14 ng/mL, sensitivity = 65%, specificity = 66%) to diagnosis MASLD (p < 0.05). MS with confirmation ELISA identified SHBG and ADH4 as potential biomarkers of pediatric MASLD.
format Article
id doaj-art-05c84aa381674add8f0882e8d5a72b1b
institution OA Journals
issn 1752-8054
1752-8062
language English
publishDate 2025-06-01
publisher Wiley
record_format Article
series Clinical and Translational Science
spelling doaj-art-05c84aa381674add8f0882e8d5a72b1b2025-08-20T02:22:10ZengWileyClinical and Translational Science1752-80541752-80622025-06-01186n/an/a10.1111/cts.70271Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver DiseaseDiego Paine‐Cabrera0Lisa K. Harvey1Michele T. Pritchard2John Thyfault3Antonio Artigues4Udayan Apte5Voytek Slowik6Department of Pharmacology Toxicology and Therapeutics, University of Kansas Medical Center Kansas City Kansas USADivision of Gastroenterology Hepatology, and Nutrition, Children's Mercy—Kansas City Kansas City Missouri USADepartment of Pharmacology Toxicology and Therapeutics, University of Kansas Medical Center Kansas City Kansas USADepartment of Molecular and Integrative Physiology University of Kansas Medical Center Kansas City Kansas USADepartment of Biochemistry and Molecular Biology University of Kansas Medical Center Kansas City Kansas USADepartment of Pharmacology Toxicology and Therapeutics, University of Kansas Medical Center Kansas City Kansas USADivision of Gastroenterology Hepatology, and Nutrition, Children's Mercy—Kansas City Kansas City Missouri USAABSTRACT Metabolic dysfunction‐associated liver disease (MASLD) is a leading cause of liver disease in children. There is a paucity of data on potential biomarkers and therapeutic targets, especially in pediatric MASLD. We used mass spectrometry (MS)‐mediated proteomics followed by enzyme‐linked immunosorbent assay (ELISA) to identify potential biomarkers and therapeutic targets in pediatric MASLD. Serum samples were collected from pediatric subjects without (n = 56) and with MASLD (n = 72). Initial screen using MS‐based proteomics identified 6 upregulated (adenosine deaminase 2, sex hormone‐binding globulin (SHBG), inter‐alpha‐trypsin inhibitor heavy chain H1 (ITIH1), fructose‐bisphosphate aldolase A, type II cytoskeletal 2 epidermal keratine, N‐acetylmuramoyl‐L‐alanine amidase) and 3 downregulated (alcohol dehydrogenase 4 (ADH4), fructose‐bisphosphate aldolase B (ALDOB), serum albumin) proteins in the MASLD group. Confirmatory studies using ELISA were performed for the 2 strongest upregulated proteins (SHBG and ITIH1) and two top downregulated proteins (ADH4 and ALDOB). Correlation of ELISA results with clinical data revealed that SHBG had strong associations with BMI, ALT, and HgbA1c (p < 0.05). ADH4 had strong associations with BMI and HgbA1c (p < 0.05). ITIH1 and ALDOB had no strong correlations with common clinical parameters of MASLD. Area under ROC Curve revealed statistically significant ability of SHBG (494 nmol/L, sensitivity = 98%, specificity 80%) and ADH4 (2.14 ng/mL, sensitivity = 65%, specificity = 66%) to diagnosis MASLD (p < 0.05). MS with confirmation ELISA identified SHBG and ADH4 as potential biomarkers of pediatric MASLD.https://doi.org/10.1111/cts.70271childhoodhepatologymetabolic syndromeobesityproteome
spellingShingle Diego Paine‐Cabrera
Lisa K. Harvey
Michele T. Pritchard
John Thyfault
Antonio Artigues
Udayan Apte
Voytek Slowik
Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease
Clinical and Translational Science
childhood
hepatology
metabolic syndrome
obesity
proteome
title Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease
title_full Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease
title_fullStr Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease
title_full_unstemmed Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease
title_short Proteomics Used in Identifying Novel Correlates of Disease in Pediatric Metabolic Dysfunction‐Associated Steatotic Liver Disease
title_sort proteomics used in identifying novel correlates of disease in pediatric metabolic dysfunction associated steatotic liver disease
topic childhood
hepatology
metabolic syndrome
obesity
proteome
url https://doi.org/10.1111/cts.70271
work_keys_str_mv AT diegopainecabrera proteomicsusedinidentifyingnovelcorrelatesofdiseaseinpediatricmetabolicdysfunctionassociatedsteatoticliverdisease
AT lisakharvey proteomicsusedinidentifyingnovelcorrelatesofdiseaseinpediatricmetabolicdysfunctionassociatedsteatoticliverdisease
AT micheletpritchard proteomicsusedinidentifyingnovelcorrelatesofdiseaseinpediatricmetabolicdysfunctionassociatedsteatoticliverdisease
AT johnthyfault proteomicsusedinidentifyingnovelcorrelatesofdiseaseinpediatricmetabolicdysfunctionassociatedsteatoticliverdisease
AT antonioartigues proteomicsusedinidentifyingnovelcorrelatesofdiseaseinpediatricmetabolicdysfunctionassociatedsteatoticliverdisease
AT udayanapte proteomicsusedinidentifyingnovelcorrelatesofdiseaseinpediatricmetabolicdysfunctionassociatedsteatoticliverdisease
AT voytekslowik proteomicsusedinidentifyingnovelcorrelatesofdiseaseinpediatricmetabolicdysfunctionassociatedsteatoticliverdisease